GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody
Open accessThe DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide 1 (GLP-1) analogs are increasingly being used in the treatment of type 2 diabetes. It is clear that these drugs lower blood glucose through an increase in insulin secretion and a lowering of glucagon secretion; in addition, they lower body weight and systolic blood pressure and increase heart rate. Using a new monoclonal antibody for immunohistochemistry, we detected GLP-1 receptor (GLP-1R) in important target organs in humans and monkeys. In the pancreas, GLP-1R was predominantly localized in β-cells with a markedly weaker expression in acinar cells. Pancreatic ductal epithelial cells did not express GLP-1R. In the kidney and lung, GLP-1R was exclusively expressed in smooth muscle cells in the walls of arteries and arterioles. In the heart, GLP-1R was localized in myocytes of the sinoatrial node. In the gastrointestinal tract, the highest GLP-1R expression was seen in the Brunner's gland in the duodenum, with lower level expression in parietal cells and smooth muscle cells in the muscularis externa in the stomach and in myenteric plexus neurons throughout the gut. No GLP-1R was seen in primate liver and thyroid. GLP-1R expression seen with immunohistochemistry was confirmed by functional expression using in situ ligand binding with 125I-GLP-1. In conclusion, these results give important new insight into the molecular mode of action of GLP-1 analogs by identifying the exact cellular localization of GLP-1R.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, GLP-1R is present beyond the confines of the pancreas and extends to a multitude of organs and tissues throughout the body. Its extensive distribution and involvement in diverse physiological processes emphasize the important role of GLP-1R beyond the regulation of glucose metabolism.38–40”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [38]
In the citing paper
“Nevertheless, studies using antibodies that appear to be specific for this receptor are consistent with results from gene expression studies, demonstrating staining for the GLP-1 receptor in human and primate kidney in juxtaglomerular cells (8).”
From GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity (2025) · cites this paper as [8]
In the citing paper
“The major site of expression appears to be in the renin-expressing juxtaglomerular cells (8).”
From GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity (2025) · cites this paper as [8]
In the citing paper
“despite only modest expression of the GLP-1 receptor in the kidney”
From GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity (2025) · cites this paper as [8]
In the citing paper
“In contrast, in primate and human thyroids, GLP-1R has either not been detected (74) or only found in small fractions of healthy C cells (75), and treatment with liraglutide does not stimulate calcitonin secretion (76).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [74]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Thorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793 · cited 1×
“This strain of mice is on a C57BL background and is derivedfromthepreviouslydescribedGLP-1Rknockoutstrain(20) custom bred by Novo Nordisk A/S at Taconic.”
MethodBjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672 · cited 2×
“In situ ligand binding for functional GLP-1R localization was performed as described previously, apart from the use of (125)IGLP-1 (7–36) (NEX3080; PerkinElmer) instead of (125)I-exendin (9–39) (21, 22).”
MethodSelf-citationTruncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670 · cited 1×
“GLP-1 has been shown to inhibit gastric acid secretion and gastric motility (36), and these effects fit well with our GLP-1R IHC findings.”
ResultTissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor
Bullock, B. P., Heller, R. S., & Habener, J. F. (1996) · Endocrinology · doi:10.1210/en.137.7.2968 · Cited by 618 · cited 5×
“1284 Pyke et al Immunolocalization of GLP-1R Endocrinology, April 2014, 155(4):1280–1290”
BackgroundInfluentialSelf-citationCentral administration of GLP-1-(7-36) amide inhibits food and water intake in rats
Tang-Christensen, M., Larsen, P. J., Goke, R., Fink-Jensen, A., Jessop, D. S., Moller, M., & Sheikh, S. P. (1996) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1996.271.4.r848 · Cited by 597
Kim, M., Platt, M. J., Shibasaki, T., Quaggin, S. E., Backx, P. H., Seino, S., Simpson, J. A., & Drucker, D. J. (2013) · Nature Medicine · doi:10.1038/nm.3128 · Cited by 514
GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting
Korner, M., Stockli, M., Waser, B., & Reubi, J. C. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.038679 · Cited by 477 · cited 4×
“The low-level GLP-1R expression in acinar cells reported in this study corresponds well with previous reports using ISLB on normal human pancreas (8, 25).”
BackgroundResultInfluentialWei, Y., & Mojsov, S. (1995) · FEBS Letters · doi:10.1016/0014-5793(94)01430-9 · Cited by 450
Campos, R. V. (1994) · Endocrinology · doi:10.1210/en.134.5.2156 · Cited by 353
Cited by
Items 701–800 of 880
Regulatory cycles of orexin and glucagon-Like peptide-1 in postviral syndromes
Ruhrländer, J., Schieffer, E., & Schieffer, B. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag009 · Cited by 2
Repetti, G. G., Abel, E. D., Tontonoz, P., & Sallam, T. (2026) · Circulation Research · doi:10.1161/circresaha.126.328680 · Cited by 3
Braha, A., Timar, B., Sturza, A., & Timar, R. Z. (2026) · Medicina · doi:10.3390/medicina62081509 · Cited by 2
“…that GLP-1 receptors may be expressed in several renal compartments, including proximal tubular cells and preglomerular vascular smooth muscle cells, but their precise localization and abundance remain controversial and appear to depend on species, disease state, and detection methods [41,46].”
Roan, J., & Tseng, W. (2016) · Cardiovascular Pharmacology Open Access · doi:10.4172/2329-6607.1000169 · Cited by 1
“GLP-1R is ubiquitously expressed in extrapancreatic tissues or cells including the stomach, intestine, sinoatrial node myocytes, endothelial and smooth muscle cells [6,9].”
BackgroundGLP-1 enhances hyperpolarization-activated currents of mouse cerebellar Purkinje cell in vitro
Liu, Y., Cao, L.-X., Wang, W., Piao, Y.-R., Wang, J.-Y., Chu, C., Bing, Y.-H., & Qiu, D. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1126447 · Cited by 3
“GLP1 receptor is a G-protein-coupled receptor that is widely expressed in the paraventricular nucleus, arcuate nucleus, ventral tegmental area, nucleus tractus solitaries, and cerebellum (Campos et al., 1994; Dunphy et al., 1998; Pyke et al., 2014; Cork et al., 2015; Heppner and Perez-Tilve, 2015; Jensen et al., 2018).”
BackgroundGIP und GLP-1-Rezeptoragonismus in der Therapie des Typ 2 Diabetes mit Fokus auf Tirzepatid
Nauck, M. A., Blüher, M., Meyhöfer, S. M., Heitmann, E., & Görgens, S. W. (2023) · Diabetologie und Stoffwechsel · doi:10.1055/a-2102-2436 · Cited by 3
“Aufgrund der Tatsache, dass GIPR in diver-sen Geweben – einschließlich Bauchspeicheldrüse, Fettgewebe, Magen-Darm-Trakt, Herz, Hypophyse, Nebennierenrinde und Ge-hirn – exprimiert werden, besitzt es vielfältige biologische Wirkungen [45, 46, 47].”
BackgroundTomlinson, B., & Chan, P. (2024) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2341882 · Cited by 2
“This may be related to an effect on the sinoatrial node which contains GLP-1 receptors [29].”
BackgroundLiao, H., Cheng, C., Chen, H., Chen, J., Pan, H., Huang, T., & Wu, V. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae385 · Cited by 4
“DPP4is increase GLP-1, glucagon-like peptide-1 ( GLP-1) levels, and GLP-1 receptors have been identified in various organs [27 ].”
Impact of glucagon-like peptide-1 receptor agonists on hypertension management: a narrative review
Oliveira-Gomes, D. D., Pingili, A., Inglis, S. S., Mandras, S. A., Loro-Ferrer, J. F., & daSilva‐deAbreu, A. (2025) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001225 · Cited by 2
GLP-1 Receptor Agonists for the Treatment of Diabetes and Obesity
Palani, A., Zhou, Y., Halleck, M. M., & Carrington, P. E. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.13765-5 · Cited by 3
Zhang, L., & Thurber, G. M. (2017) · Springer eBooks · doi:10.1007/978-3-319-61401-4_8 · Cited by 4
Yamashita, S., Kawakami, Y., Satō, H., Sugitani, S., Goto, M., & Kato, N. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172521 · Cited by 2
Kondo, N., Oishi, A., Hirata, M., & Temma, T. (2020) · Annals of Nuclear Medicine · doi:10.1007/s12149-020-01540-0 · Cited by 3
Gorvin, C. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00020-7 · Cited by 2
Abood, A., Awad, H., & Hassan, S. M. (2021) · Ain Shams Medical Journal · doi:10.21608/asmj.2021.167313 · Cited by 3
“The expression of GLP-1 receptors is not limited to the pancreas and is present in other non-digestive organs including the kidney, the heart and the blood vessels (13,14) .”
BackgroundÇakmak, R., Çaklılı, Ö. T., Tekin, S., Hacışahinoğulları, H., Tanrıkulu, S., Koc, M. S., & Dınççağ, N. (2021) · Biomarkers in Medicine · doi:10.2217/bmm-2021-0318 · Cited by 2
Anaparti, V. (2018) · Materials and Methods · doi:10.13070/mm.en.8.2668 · Cited by 2
GLP-1R is downregulated in beta cells of NOD mice and T1D patientsPreprint
Recino, A., Barkan, K., Schmidt-Christensen, A., Nilsson, J., Holmes, N., Howie, D., Holmberg, D., Larsson, P. G., Flodström‐Tullberg, M., Laraia, L., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/845776 · Cited by 2
“For staining, cells were permeabilised with 0.5% Triton X-100 for 5mins in room temperature (RT) and blocked in 3% BSA/5% FCS/PBS for 1h. Staining was performed at RT for 1h by using Mab 7F38 mouse anti-GLP-1R (DSHB, University of Iowa) 1.5μg/ml, guinea pig anti Insulin (DAKO), rabbit anti-Calnexin (ENZO), rabbit anti…”
MethodInfluentialIn vivo functional profiling and structural characterisation of the human Glp1r A316T variantPreprint
Eid, L. E., Deane-Alder, K., Rujan, R., Mariam, Z., Oqua, A. I., Manchanda, Y., Belousoff, M. J., de la Serna, J. B., Sloop, K. W., Rutter, G. A., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.19.619191 · Cited by 2
Kesavadev, J., Unnikrishnan, A. G., Sanyal, D., Aneja, P., & Saboo, B. (2022) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_17_22 · Cited by 1
Obesity and Atrial Fibrillation: Therapeutic Perspective for GLP-1 Analogs
Szołkiewicz-Płatkowska, A., & Orczykowski, M. (2024) · In a good rythm · doi:10.5604/01.3001.0054.6436 · Cited by 1
Rico-Fontalvo, J. E., Reina, M., Soler, M. J., Unigarro-Palacios, M., Castañeda-González, J. P., Quintero, J. J., Raad-Sarabia, M., de Moraes, T. P., & Daza-Arnedo, R. (2024) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2024-0101pt · Cited by 4
The transformative breakthroughs in GLP-1 research recognized by the 2024 Lasker~DeBakey award
Zhou, Y.-F., Li, Q., Wang, L.-G., Lu, Y., Wang, Y., & Yang, J. (2024) · Current Medicine · doi:10.1007/s44194-024-00041-w · Cited by 1
Kondo, N., Yonezawa, M., Hirano, F., & Temma, T. (2025) · Molecules · doi:10.3390/molecules30051011 · Cited by 1
“…corresponded to insulin-positive regions in the immunohistochemically stained serial sections, confirming the specific targeting of pancreatic β -cells [35,36] (Figure 4b). immunohistochemically stained serial sections, con fi rming the speci fi c targeting of pancreatic β -cells [35,36] (Figure 4b”
Alicic, R. Z., & Neumiller, J. J. (2025) · Cardiology Clinics · doi:10.1016/j.ccl.2024.12.003 · Cited by 1
Ma, Z., Wang, B., Li, D., & Chen, X. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.70087 · Cited by 1
“Although the precise mechanism was not yet fully understood, GLP1RAs appeared to exert their effects indirectly, as the liver lacked GLP1 receptors 24 .”
Jia, W., Li, X., & Qi, S. (2025) · Materials Technology · doi:10.1080/10667857.2025.2517670 · Cited by 2
“GLP-1RA is a commonly used medication for the treatment of obesity and NAFLD, but it is worth noting that there is no expression of GLP-1 R in the liver, and thus the mechanism of action of GLP-1RA is not entirely clear [10,11].”
Advancing Heart Failure Care: Breakthroughs and Emerging Strategies
Tedeschi, A., Barocelli, F., Gerra, L., Breviario, F., Palazzini, M., Conti, N., Ferraro, S., Bolognesi, M. G., Spigno, F. D., Gentile, P., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14207253 · Cited by 5
“Its physiological actions include glucose-dependent insulin secretion, inhibition of glucagon release, delayed gastric emptying, appetite suppression, and enhanced satiety [44].”
Morrow, N. M., Hanson, A. A., Fong-McMaster, C., Livingston, D. B. H., Osman, H., Hamilton, L., Trzaskalski, N. A., Locatelli, C. A. A., Bellefleur, M. N., Messika-Zeitoun, E., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-09281-4 · Cited by 1
“Speci fi cally, duodenal Brunner ’ s glands, stomach gland parietal cells 26 , the myenteric nerve plexus, and crypt Paneth cells express Glp1r mRNA 27,28 .”
Peptide drugs for obesity and type 2 diabetes mellitus: an overview of clinical trials
Barzgar, H., Darmadi, D., Nafisa, J., Narkulov, S., & Sviridova, M. B. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120772 · Cited by 2
Glucagon-Like Peptide-1 Receptor Agonists: A Novel Indication for Substance Use Disorders?
Ftiha, F., Ftiha, J., Parikh, M. A., Frishman, W. H., & Peterson, S. J. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000001145 · Cited by 1
Jiang, L., He, L., Li, D., Luo, X., Yang, M., Wu, H., & Long, H. (2026) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2026.100349 · Cited by 1
“Existing studies have shown that GLP-1R is not only expressed in pancreatic islets but also on various immune and structural cells in the lung [15,16].”
Huang, Y., Lin, X., Deng, M., Tang, Y., Li, S., Xu, B., Zeng, W., Chen, Z., Hou, X., Lin, Z., et al. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106141 · Cited by 3
Helal, M. M., Almosilhy, N. A., Abo‐elnour, D. E., Jaffal, R., Allam, E. G., Almosilhy, M. A., Batarseh, S. F., & Meshref, M. M. (2026) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2026.2627901 · Cited by 3
“GLP-1R expression has been identified in multiple tissues and organs beyond the pancreas, including the CNS, cardiovascular system, gastro-intestinal tract, kidneys, lungs, and skin, highlighting its diverse physiological roles beyond glucose regulation (191,192).”
Lin, M.-P., Xue, B.-J., & Bai, X. (2026) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-026-10759-7 · Cited by 2
“Con-troversially, Pyke et al. [23] identified GLP-1R by immunohistochemistry (IHC) using an extensively validated monoclonal antibody (MAb 3F52), and found that in the hearts of normal primates, GLP-1R was only expressed on myocytes in the sinoatrial node (SA node).”
Cetiner, S. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02232-y · Cited by 1
Merrild, C., Johansen, V. B. I., Clemmensen, C., & Ranea‐Robles, P. (2026) · The Journal of Physiology · doi:10.1113/jp289817 · Cited by 1
Acute Contractile Effects of Glucagon-like-Peptide-1 Receptor Agonists in the Human Heart
Neumann, J., Kirchhefer, U., Hofmann, B., & Gergs, U. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18040447 · Cited by 1
Zawadzki, M., & Karczewska‐Kupczewska, M. (2026) · Cardiovascular Therapeutics · doi:10.1155/cdr/8388511 · Cited by 1
Cui, S., Kong, H., Tian, Y., Li, D., Li, C. J., Ban, X., Gu, Z., & Li, Z. (2026) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2026.2691225 · Cited by 2
“Early studies have detected low-level expression of GLP-1R in pancreatic acinar cells (Pyke et al. 2014), raising the possibility of direct GLP-1 action on exocrine pancreatic function.”
Contractile effects of albiglutide in the human and mouse atrium
Jn, N., Jarikova, M., Kirchhefer, U., Hofmann, B., & Gergs, U. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1831742 · Cited by 1
“In contrast, both mRNA and protein for GLP-1R have been detected in the human sinus node (45).”
Incretin-Based Therapies, Obesity-Associated Inflammation, and Atherosclerotic Cardiovascular Risk
Kafol, J., Jug, B., & Fras, Z. (2026) · Cells · doi:10.3390/cells15141293 · Cited by 1
“…protection has been demonstrated in genetically modified mouse models [72], but reproducible receptor expression in human vascular endothelial cells remains uncertain; therefore, direct endothelial signaling and indirect metabolic, neural, or paracrine mechanisms remain plausible [44,60].”
InfluentialEmerging role of GLP-1 mono, dual, and triple agonists in the management of MASH-related fibrosis
Tavaglione, F., & Loomba, R. S. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.103023 · Cited by 2
Effects of GLP-1 receptor agonists on body weight and cardiovascular outcomes: a review
van Maren, S., van Doorn, E. P. M., Smits, M. M., Tack, C. J., van Rossum, E. F. C., & Messaoudi, S. E. (2026) · Netherlands Heart Journal · doi:10.1007/s12471-026-02073-3 · Cited by 1
Falahee, B. E., Apovian, C. M., & Istfan, N. W. (2026) · Obesity · doi:10.1002/oby.70294 · Cited by 2
DPP-4-Hemmer und GLP-1-Rezeptor-Agonisten: Kardiovaskuläre Effekte
Nauck, M. A., Aziz, M. S. A. E., & Meier, J. J. (2016) · Der Diabetologe · doi:10.1007/s11428-016-0083-8 · Cited by 1
“Wenn ein spezifischer Antikörper zum Nachweis von GLP-1-Rezeptoren verwendet wird, finden sie sich im menschlichen Herzen ausschließlich im Sinusknoten [29].”
BackgroundLEADER and the new ‘cardiovascular’ glucose‐lowering agents
Livingstone, R., Boyle, J. G., & Petrie, J. R. (2016) · Practical Diabetes · doi:10.1002/pdi.2033 · Cited by 1
Reubi, J. C. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.197582 · Cited by 1
“Putting most of the above-mentioned recommendations into practice will likely prevent unnecessary controversies and reduce experimental discrepancies, as recently shown by examples in the field of receptors for somatostatin, chemokines, and glucagonlike peptide 1 (3,4,10,11,23,24).”
BackgroundTian, Q., Liu, Y., Yuan, P., Liu, J., Li, H., Han, X., Pan, C., Wu, Y., Zhou, Z., Liu, S., et al. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.134328 · Cited by 1
Noncardiovascular-derived therapeutic peptidomimetics in cardiovascular disease
Litmanovich, A., Ertracht, O., Blumberg, Y., Saad, M., Moady, G., & Qvit, N. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-820141-1.00013-3 · Cited by 2
Lubberding, A. F., Holst, J. J., & Madsbad, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99991-5.00017-6 · Cited by 1
Advances in the Management of Diabetes and Overweight using Incretin-based Pharmacotherapies
Prajapati, S. (2023) · Current Diabetes Reviews · doi:10.2174/0115733998256797231009062744 · Cited by 1
Chianelli, M., Albanese, A., Carabotti, M., Casarotto, D., Pergola, G. D., Disoteo, O., Grandone, I., Medea, G., Nisoli, E., Raffaelli, M., et al. (2024) · L Endocrinologo · doi:10.1007/s40619-024-01417-8 · Cited by 3
“A differenza degli altri farmaci della classe dei GLP-1 agonisti, liraglutide attraversa la barriera emato-encefalica [109].”
Nedyalkova, M., Robeva, R. N., Romanova, J., Yovcheva, K., Lattuada, M., & Simeonov, V. (2024) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2024.2330714 · Cited by 1
“GLP-1 effects are mediated through the G-protein-coupled GLP-1 receptor (GLP-1R), which is widely distributed in the arterial walls, pancreas, kidney, heart and brain tissues (Moon et al., 2012; Pyke et al., 2014).”
GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Game Charger in the Field?
Doumani, G., Theofilis, P., Tsimihodimos, V., & Kalaitzidis, R. (2024) · Life · doi:10.3390/life14111478 · Cited by 5
Enterohormones and the Response to Critical Illness
Plummer, M. P., Blaser, A. R., & Deane, A. M. (2016) · Springer eBooks · doi:10.1007/978-3-319-27687-8_13 · Cited by 1
Schmidt, J. B., Sjödin, A. M., Stevner, L., Ritz, C., Michaelsen, N. B., Thomsen, A. B., Holst, J. J., & Astrup, A. V. (2016) · Physiological Reports · doi:10.14814/phy2.12980 · Cited by 2
“There are data indicating that GLP-1Rs are only present on the pancreatic b-cells, while other data indicate that the acinar cells of the exocrine pancreas also contain GLP-1Rs at a lower density (Pyke et al. 2014; Waser et al. 2015).”
BackgroundDo DPP-4 inhibitors improve endothelial cell function?
Nomoto, H., Miyoshi, H., Nakamura, A., Atsumi, T., Manda, N., Kurihara, Y., & Aoki, S. (2017) · doi:10.35841/cardiology.1.1.12-14 · Cited by 1
“The effects of DPP-4 inhibitors on atherosclerosis were thought to be partially due to augmented GLP-1 signaling, but it is not clear whether endothelium expresses the GLP-1 receptor [10].”
BackgroundInflammatory Mechanisms in Diabetic Kidney Disease
Alicic, R. Z., Cox, E. J., Neumiller, J. J., & Tuttle, K. R. (2020) · Springer eBooks · doi:10.1007/978-3-030-53370-0_32 · Cited by 1
Miller, C. O., & Cao, J. (2021) · Metabolites · doi:10.3390/metabo11110712 · Cited by 1
“Since liver does not express the GLP1R [18], the perfused liver provides a unique paradigm to evaluate potential GLP1R/GcgR agonists for effects on the GcgR alone.”
BackgroundInfluentialGlucagon-like Peptide-1 Receptor Agonists (GLP1-RA)
Alicic, R. Z., Cox, E. J., Neumiller, J. J., & Tuttle, K. R. (2022) · Springer eBooks · doi:10.1007/978-3-030-86020-2_26 · Cited by 2
Reply: From Mice to Humans: The Exocrine Pancreas Does Not Matter in Human GLP-1 Receptor Imaging
Thurber, G. M. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262029 · Cited by 1
“The human pancreas shows an even higher endocrine-to-exocrine ratio (3), and single-cell RNA sequencing demonstrates specificity of the GLP-1R for human b- and d-cells (5).”
BackgroundGLP-1R activation is a key pathway to alleviate the metabolic disorder in L02 cellsPreprint
Tian, Q. J., Liu, Y., Liu, J., Yuan, P., Li, H., Han, X.-F., Pan, C., Duan, S., & Xia, K. (2020) · doi:10.21203/rs.3.rs-29811/v1 · Cited by 1
“It is worth noting that a research using RNA and in situ hybridization have not detected expression of GLP-1R in hepatocytes (Naim et al., 2013, Pyke et al., 2014).”
BackgroundNjei, B. M., Al‐Ajlouni, Y. A., Lemos, S. Y., Ugwendum, D. F., Ameyaw, P. A., Njei, L., & Boateng, S. (2024) · doi:10.22541/au.171585503.34303032/v1 · Cited by 1
Bleckwehl, T., Schumacher, D., Heymanns, C., Maryam, S., Andries, A.-S., Jurgens, S. J., Amrute, J., Hoeft, K., Wu, X., Liu, Y., et al. (2025) · medRxiv · doi:10.1101/2025.10.09.25337646 · Cited by 5
Self-citationGLP-1 receptor agonists and heart failure: insights from human genetics
Emanuelsson, F., & Benn, M. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf1058 · Cited by 1
Терапия, основанная на инкретинах: почечные эффекты
Korbut, A. I., & Klimontov, V. V. (2016) · Diabetes Mellitus
Action of Incretins on the Pancreatic α Cell: Control of Glucagon Secretion
McCulloch, L. J., Godazgar, M., Rorsman, P., & Ramracheya, R. D. (2015) · IMPERIAL COLLEGE PRESS eBooks · doi:10.1142/9781783267378_0004
Auswirkungen von Liraglutid auf die Hirnaktivität
Jecht, M. (2016) · Der Diabetologe · doi:10.1007/s11428-016-0133-2
Vergès, B. L. (2017) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(17)30055-x · Cited by 1
Characterization of Novel Glucagon Receptor Interactors that Modify Receptor Activity
Froese, D. S. (2015) · TSpace (University of Toronto)
Aragão, G. C. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2017.tde-09032017-123135
Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes
Cusi, K. J. (2017) · Contemporary diabetes · doi:10.1007/978-3-319-61013-9_4
Stephen, S., & Ramracheya, R. D. (2017) · Springer eBooks · doi:10.1007/978-3-319-60408-4_1
The Cardiac Glucagonlike Peptide-1 Receptor: Whither Art Thou?
Brubaker, P. L. (2018) · Endocrinology · doi:10.1210/en.2018-00186
Molecular Imaging Agent Design for Quantifying Beta Cell Mass in Type 1 Diabetes
Zhang, L. (2017) · Deep Blue (University of Michigan) · Cited by 1
Generation and use of new tools for the characterisation of gut hormone receptors
Biggs, E. K. (2018) · Apollo (University of Cambridge) · doi:10.17863/cam.37487
Effects of Exercise on Incretin Hormones
Toghi-Eshghi, S. R. (2018) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r30g3hd88
Zhang, Q., Zhang, X., & Niu, C.-Y. (2020) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v28.i11.393
Incretin-based treatment of diabetes and cardiovascular complications
Haluzík, M. (2020) · Vnitřní lékařství · doi:10.36290/vnl.2020.012
“Kardiovaskulární účinky GLP-1, gliptinů a GLP-1 agonistů Receptory pro GLP‐1 jsou kromě gastrointestinálního traktu přítomny také v centrálním nervovém systému, v myokardu (zde zřejmě převážně v sinoatriálním nodu), v buňkách hladké svaloviny cév, v endoteliálních buňkách a v makrofázích (26).”
GLP-1R Agonists & Cardiac Energy Metabolism in Type 2 Diabetes
Almutairi, M. G. (2019) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3-fhr3-cr50
Mulaik, M. W. (2013) · PubMed
Glucagon-Like Peptide-1 Receptor Agonist Effects on Gastric Motility: A Systematic Review
Wongjarupong, N., Al-Hameed, M., Suchartikitwong, S., Assavapongpaiboon, B., & Salehian, B. (2020) · Diabetes & its Complications · doi:10.33425/2639-9326.1076
“The GLP-1 receptors are located in various organs, particularly pancreas, gastrointestinal tract and hypothalamus [6,7].”
BackgroundTian, Q. J., Liu, Y., Yuan, P., Liu, J., Li, H., Han, X., Pan, C., Duan, S., & Xia, K. (2020) · doi:10.21203/rs.3.rs-29811/v2
The pathophysiology of gut–liver connection
Maroni, L., Fianchi, F., Miele, L., & Svegliati‐Baroni, G. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821927-0.00002-4
Glucagon‐Like Peptide‐1 Receptor Activators
Wagner, M., Evers, A., Bossart, M., & Konkar, A. A. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc268
(2021) · Український медичний часопис · doi:10.32471/umj.1680-3051.146.220199
Treatment with GLP-1 Receptor Agonists
Madsbad, S., & Holst, J. J. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_20 · Cited by 1
Advances in Biological and Clinical Research of GLP-1 Receptor Agonists
李, 鑫. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.124430
Lin-quan, Z. (2021) · American Journal of Biomedical Science & Research · doi:10.34297/ajbsr.2021.11.001657
“By stimulating the central reward system, it can increase the sense of satiety, reduce food intake, and have the effect of losing weight and reducing blood sugar [59].”
BackgroundGlucagon Like Peptide-1: More than Glucose Control and Weight ReductionPreprint
Chen, Y., Shao, S., Zhang, X., Xu, Q., & Pan, R. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4161722
Expert Insights for PCPs in Managing CKD in T2DM
Wu, Y. T. A. (2022) · The Singapore Family Physician · doi:10.33591/sfp.48.3.u5
Mechanisms of GLP‒1 Receptor Agonists on the Cardio-Renal Protective Effects
Kuriyama, S., & Matsumoto, K. (2022) · Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics · doi:10.3999/jscpt.53.6_249
GLP-1 analogues in the treatment of obesity and non-alcoholic fatty liver disease
Deska, K., Bąk, B., Kosmalski, M., & Pietras, T. (2023) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.2478/ahem-2023-0001
Receptor mediated tissue targeted delivery of oligonucleotide
Nagata, T., & Yokota, T. (2023) · Drug Delivery System · doi:10.2745/dds.38.8
Research Progress on Mechanism of Glucagon-Like Peptide-1 and Aortic Valve Calcification
张, 盼. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.134905
Nielsen, T. A. (2023) · VBN Forskningsportal (Aalborg Universitet) · doi:10.54337/aau588597746
Investigating Semaglutide in Adult Patients on Body Weight Compared with Other GLP-1 Drugs
Farrash, S., Aleisa, L., Alhazmi, N. Z., Almatrafi, N., Alharbi, T., Kelantan, S., Alotaibi, L., Hunaydi, W., Alnimari, S., Alqarni, N., et al. (2023) · International Journal Of Pharmaceutical Research And Allied Sciences · doi:10.51847/j9zsdr5dno
Investigating incretins: a review of the use of GLP-1 and GIP receptor agonists for weight loss
Miller, A. (2024) · Journal of Aesthetic Nursing · doi:10.12968/joan.2024.13.1.6
Metadata
- Authors
- Pyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Department of Diabetes Structural Biology (S.R.-R.), Novo Nordisk, 2880 Bagsværd, Denmark
- Rigshospitalet (DK)
- Corresponding author
- Knudsen, Lotte Bjerre
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2014-04-01
- Volume
- 155
- Issue
- 4
- Pages
- 1280-1290
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W1979288606
- Cited by
- 876
- References
- 37
- Citations by year
- 2026: 99 · 2025: 91 · 2024: 103 · 2023: 56 · 2022: 70 · 2021: 64 · 2020: 64 · 2019: 57 · 2018: 60 · 2017: 64 · 2016: 61 · 2015: 58 · 2014: 27
- FWCI
- 56.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Endocrinology (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- GLP-1 receptor, glucagon-like peptide-1, receptor localization, type 2 diabetes, GLP-1 analogues, pancreatic beta cells, sinoatrial node, Brunner's glands, myenteric neurons, smooth muscle cells, kidney, heart, gastrointestinal tract, receptor expression
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Exenatide, Insulin Secretion, Animals, Haplorhini, Antibodies, Monoclonal, Blood Pressure, Body Weight, Cell Line, Duodenum, Glucagon, Cricetinae, Heart Rate, Humans, Insulin, Ligands, Mice, Inbred C57BL, Peptides, Protein Binding, Tissue Distribution, Transfection, Venoms, Receptors, Glucagon, Mice, Knockout, Mice, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.